Fish Oil Supplementation and Vascular Function in Hypertensive Patients With Hypertriglyceridemia
NCT ID: NCT01480687
Last Updated: 2011-11-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE4
52 participants
INTERVENTIONAL
2011-05-31
2012-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Omega-3 fatty acid
DHA-EPA
1800 mg/day
Ciprofibrate
Ciprofibrate
100 mg/day
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
DHA-EPA
1800 mg/day
Ciprofibrate
100 mg/day
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients with serum triglycerides levels ≥ 150 mg/dl and \<500 mg/dl
* Patients on stable antihypertensive medication for at least 4 weeks
* Patients with food consumption maintained for at least 4 weeks
Exclusion Criteria
* Secondary hypertension
* Hormone replacement therapy
* Diabetes mellitus
* Chronic kidney disease
* Known coronary artery disease
* Previous stroke
* Dyslipidemia severe, with LDL cholesterol\> 160 mg/dL or triglycerides ≥ 500 mg/dl
* Use of statins or beta blockers
40 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Rio de Janeiro State Research Supporting Foundation (FAPERJ)
OTHER_GOV
Hospital Universitario Pedro Ernesto
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Mario Fritsch Neves
MD, PhD
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Marcela A Casanova, MSc
Role: PRINCIPAL_INVESTIGATOR
State University of Rio de Janeiro
Mario F Neves, MD, PhD
Role: STUDY_CHAIR
State University of Rio de Janeiro
Wille Oigman, MD, PhD
Role: STUDY_CHAIR
State University of Rio de Janeiro
Fernanda J Medeiros, PhD
Role: STUDY_CHAIR
Federal University of the State of Rio de Janeiro
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hospital Universitario Pedro Ernesto
Rio de Janeiro, RJ, Rio de Janeiro, Brazil
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Marcela A Casanova, MSc
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
FO-1800
Identifier Type: -
Identifier Source: org_study_id